a:3:{s:6:"_token";s:40:"bYpYwroMgzopTclw9GbutUtnMbM5mgHyEXpToMP6";s:9:"_previous";a:1:{s:3:"url";s:166:"https://www.pharmafocusasia.com/pressreleases/tempus-introduces-xm-to-assess-minimal-residual-disease-mrd-in-patients-with-colorectal-cancer-crc-for-research-use-only";}s:6:"_flash";a:2:{s:3:"old";a:0:{}s:3:"new";a:0:{}}}